Xcout IntelActive Biotech competitors & alternatives
The 12 closest competitors and alternatives to Active Biotech among biotech companies — ranked by similarity to what Active Biotech actually does, not by market-cap band.
Subscribe to see Active Biotech’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Active Biotech
Active Biotech is a biotechnology company that develops pharmaceutical treatments for cancer and inflammatory eye diseases, focusing on specialist indications such as hematological cancers, solid tumors, and non-infectious uveitis. Its clinical pipeline includes immunomodulating molecules and antibody-based therapies like tasquinimod, laquinimod, and naptumomab.
Active Biotech at a glance
Active Biotech is a biotech company headquartered in Sweden. Xcout tracks 6 named people at Active Biotech, including Erik Vahtola (Medicinsk chef).
Active Biotech leadership
- Erik VahtolaMedicinsk chef
- Hans KolamEkonomi- och finanschef
- Helén Tuvessonvd
- Michael ShalmiStyrelseordförande
- Aleksandar DanilovskiStyrelseledamot
- Peter ThelinStyrelseledamot
Top 12 Active Biotech competitors
Ranked by semantic similarity — how close each company is to Active Biotech by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotechnology
Immunicum AB is a Swedish biotechnology company that developed allogeneic cell-based cancer immunotherapies, including the investigational product ilixadencel. Its programs were aimed at stimulating patients’ immune systems to treat solid tumors, serving oncology patients and healthcare providers.
Similar biotech company
Arctic Bioscience is a Norwegian biotech company that develops marine-derived health products and pharmaceutical candidates, particularly based on bioactive compounds from herring roe. It serves consumers and healthcare markets with omega-3 products and investigates treatments for inflammatory and autoimmune conditions.
Biotechnology
ImmunOs Therapeutics AG is a biotechnology company that develops treatments for cancer and inflammatory diseases by harnessing the human immune system. The company focuses on immuno-oncology and autoimmune therapies through a dedicated drug pipeline.
Similar biotech company
Oncopeptides is a pharmaceutical company that develops targeted cancer therapies utilizing proprietary platforms like peptide drug conjugates. The company focuses on treating difficult-to-treat hematological diseases and rare cancers, such as multiple myeloma, aiming to provide new treatment options for patients with significant unmet medical needs.
Similar biotech company
Founded in 1996 and based in Lund, Sweden, BioInvent International AB (publ) is a clinical-stage biotechnology company dedicated to the discovery, research, and development of immuno-modulatory antibodies for cancer treatment. Its operations span Sweden, Europe, the United States, Japan, and other global regions. The company's leading therapeutic candidate, BI-1206, is under development for non-Hodgkin lymphoma and various solid tumors. BioInvent's pipeline also features projects targeting tumor-associated myeloid cells and cancer-associated regulatory T cells, which play a role in modulating the immune system. Other notable developments include BT-001 for solid tumors, and the anti-TNFR2 antibodies BI-1808 and BI-1910, intended for solid tumors and cutaneous T-cell lymphoma. BioInvent maintains strategic alliances, including a collaboration with Pfizer Inc. for antibodies against tumor-associated myeloid cells, and a co-development partnership with Transgene focused on multi-functional oncolytic viruses for solid tumors. Additionally, the company has a collaboration and supply agreement with Merck for the clinical progression of BI-1808.
Biotechnology
Affimed Therapeutics is a biotechnology company focused on developing cancer immunotherapies that recruit and activate innate immune cells, particularly natural killer (NK) cells, to attack tumor cells. Its investigational products are intended for oncology patients and are developed for use by cancer-care providers.
Biotechnology
Affibody AB is a Swedish biopharmaceutical company located in Solna that develops next-generation biopharmaceuticals based on its proprietary Affibody technology platform.
Similar biotech company
Aptose Biosciences Inc. is a clinical-stage biotechnology company that develops small molecule cancer therapeutics, focusing on precision medicines for hematologic malignancies. The company's product pipeline features investigational drug candidates such as tuspetinib and luxeptinib, which are designed to treat conditions like acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and B-cell malignancies.
Similar biotech company
Numab Therapeutics is a Swiss biotechnology company developing multispecific antibody-based medicines that modulate immune-cell interactions. Its programs target serious diseases including cancer and immune-mediated or inflammatory disorders, serving patients through development and potential partnerships with pharmaceutical companies.
Similar biotech company
TILT Biotherapeutics is a Finnish biotechnology company developing tumor-targeted immunotherapies, including oncolytic adenoviruses designed to stimulate immune responses against solid tumors. Its therapies are intended for cancer patients and are developed through clinical and pharmaceutical partnerships.
Similar biotech company
Genmab A/S, a biopharmaceutical company founded in 1999 and headquartered in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody therapies primarily for treating cancer and various other serious illnesses. The company's commercialized portfolio includes several key products: DARZALEX (daratumumab), a human monoclonal antibody for multiple myeloma (MM), non-MM blood cancers, and AL amyloidosis; teprotumumab, indicated for thyroid eye disease; ofatumumab, another human monoclonal antibody used in chronic lymphocytic leukemia (CLL) and multiple sclerosis; Amivantamab, for advanced or metastatic gastric or esophageal cancer and non-small cell lung cancer (NSCLC); and tisotumab vedotin, which targets cervical, ovarian, and solid tumors. Genmab maintains a robust pipeline of investigational medicines. These include GEN1047; DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB, both developed for solid tumors; Epcoritamab, in development for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37, aimed at hematological malignancies. Furthermore, the company has several products in Phase 2 clinical trials: Teclistamab for vaso-occlusive crises; Camidanlumab tesirine for Hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 for MM; PRV-015 for celiac disease; Mim8 for haemophilia A; and Lu AF82422 for multiple system atrophy disease. In addition to its clinical programs, Genmab is advancing approximately 20 active pre-clinical programs. Genmab fosters strategic collaborations to further its research and development efforts. It holds a commercial license and co-development agreement with Seagen Inc. for tisotumab vedotin. The company also partners with CureVac AG on the research and development of differentiated mRNA-based antibody products and with AbbVie for the development of epcoritamab. Further alliances include BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Active Biotech and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Active Biotechand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →